These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 12747904

  • 1. Combined salmeterol and fluticasone for COPD.
    Pakhale SS, Goldstein RS.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747904
    [No Abstract] [Full Text] [Related]

  • 2. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 3. Combined salmeterol and fluticasone for COPD.
    MacAllister R.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747902
    [No Abstract] [Full Text] [Related]

  • 4. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec 10; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 5. Combined salmeterol and fluticasone for COPD.
    Hyde C, Dretzke J.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747903
    [No Abstract] [Full Text] [Related]

  • 6. COPD: treatments benefit patients.
    Rennard SI.
    Lancet; 2003 Feb 08; 361(9356):444-5. PubMed ID: 12583937
    [No Abstract] [Full Text] [Related]

  • 7. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 Feb 08; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 8. Combined salmeterol and fluticasone for COPD.
    Thirstrup S, Kampmann JP.
    Lancet; 2003 May 10; 361(9369):1650-1; author reply 1652-3. PubMed ID: 12747900
    [No Abstract] [Full Text] [Related]

  • 9. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 10; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 10. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P.
    MMW Fortschr Med; 2003 Jun 12; 145(24):20. PubMed ID: 12866294
    [No Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May 12; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 12. Differentiating asthma and COPD patients.
    El-Kassimi FA.
    Chest; 2004 Aug 12; 126(2):653-4; author reply 654-5. PubMed ID: 15302761
    [No Abstract] [Full Text] [Related]

  • 13. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 12; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 14. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 12; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 15. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs.
    Suissa S.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):322-3. PubMed ID: 18676961
    [No Abstract] [Full Text] [Related]

  • 16. [Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].
    Vestbo J.
    Ugeskr Laeger; 2004 Jan 19; 166(4):271-4. PubMed ID: 14964108
    [No Abstract] [Full Text] [Related]

  • 17. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 18. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 13; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 19. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 13; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 20. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
    Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK, SCO30005 Study Group.
    Am J Respir Crit Care Med; 2006 Apr 01; 173(7):736-43. PubMed ID: 16424444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.